Truist Financial Has Lowered Expectations for Stryker (NYSE:SYK) Stock Price

Stryker (NYSE:SYK) had its price objective decreased by analysts at Truist Financial from $395.00 to $380.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price objective would indicate a potential upside of 12.51% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Barclays reiterated an “overweight” rating and set a $469.00 target price on shares of Stryker in a research report on Monday, February 2nd. William Blair reiterated an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. UBS Group dropped their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Finally, Sanford C. Bernstein boosted their target price on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $421.11.

Stryker Trading Down 1.0%

NYSE:SYK opened at $337.76 on Wednesday. The firm’s fifty day moving average is $353.28 and its 200-day moving average is $359.79. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker has a 52 week low of $319.32 and a 52 week high of $404.87. The firm has a market cap of $129.36 billion, a P/E ratio of 40.21, a P/E/G ratio of 1.99 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. During the same period in the prior year, the firm posted $4.01 EPS. The company’s quarterly revenue was up 11.4% on a year-over-year basis. Equities analysts expect that Stryker will post 13.47 earnings per share for the current year.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Sankala Group LLC acquired a new position in Stryker during the fourth quarter worth $26,000. Clayton Financial Group LLC acquired a new position in Stryker during the third quarter worth $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the fourth quarter worth $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the third quarter worth $27,000. Finally, Atlas Capital Advisors Inc. acquired a new position in Stryker during the fourth quarter worth $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.